No Data
No Data
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
The 13% Return This Week Takes Stoke Therapeutics' (NASDAQ:STOK) Shareholders One-year Gains to 116%
White Paper Shows Role of Ongoing Patient Engagement to Improve Rare Disease Clinical Trials, Costs, and Success Rates
Shareholders Can't Ignore US$523k Of Sales By Stoke Therapeutics Insiders
Is It a Good Idea to Invest in Stoke Therapeutics Stock Now?
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35